1. Home
  2. ATEN vs NTLA Comparison

ATEN vs NTLA Comparison

Compare ATEN & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATEN
  • NTLA
  • Stock Information
  • Founded
  • ATEN 2004
  • NTLA 2014
  • Country
  • ATEN United States
  • NTLA United States
  • Employees
  • ATEN N/A
  • NTLA N/A
  • Industry
  • ATEN EDP Services
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • ATEN Technology
  • NTLA Health Care
  • Exchange
  • ATEN Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • ATEN 1.3B
  • NTLA 1.2B
  • IPO Year
  • ATEN 2014
  • NTLA 2016
  • Fundamental
  • Price
  • ATEN $17.61
  • NTLA $12.32
  • Analyst Decision
  • ATEN Strong Buy
  • NTLA Buy
  • Analyst Count
  • ATEN 4
  • NTLA 20
  • Target Price
  • ATEN $21.50
  • NTLA $25.48
  • AVG Volume (30 Days)
  • ATEN 425.6K
  • NTLA 10.8M
  • Earning Date
  • ATEN 11-04-2025
  • NTLA 11-06-2025
  • Dividend Yield
  • ATEN 1.37%
  • NTLA N/A
  • EPS Growth
  • ATEN 21.29
  • NTLA N/A
  • EPS
  • ATEN 0.69
  • NTLA N/A
  • Revenue
  • ATEN $276,445,000.00
  • NTLA $52,857,000.00
  • Revenue This Year
  • ATEN $10.53
  • NTLA $9.20
  • Revenue Next Year
  • ATEN $7.41
  • NTLA N/A
  • P/E Ratio
  • ATEN $25.34
  • NTLA N/A
  • Revenue Growth
  • ATEN 11.04
  • NTLA 14.99
  • 52 Week Low
  • ATEN $13.81
  • NTLA $5.90
  • 52 Week High
  • ATEN $21.90
  • NTLA $28.25
  • Technical
  • Relative Strength Index (RSI)
  • ATEN 46.39
  • NTLA 33.43
  • Support Level
  • ATEN $17.31
  • NTLA $11.63
  • Resistance Level
  • ATEN $17.95
  • NTLA $13.60
  • Average True Range (ATR)
  • ATEN 0.45
  • NTLA 1.66
  • MACD
  • ATEN -0.01
  • NTLA -1.70
  • Stochastic Oscillator
  • ATEN 42.86
  • NTLA 3.76

About ATEN A10 Networks Inc.

A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: